AMPAC Fine Chemicals

What AMPAC Fine Chemicals does

AMPAC Fine Chemicals is a US-based specialty chemicals firm founded in 2005 and headquartered in Rancho Cordova, California. The company operates in the small-molecule pharmaceutical CDMO space, producing fine chemicals, controlled substances, and highly potent active pharmaceutical ingredients (HPAPIs) under cGMP compliance. With a workforce of 501–1,000 employees, AMPAC serves pharmaceutical drugmakers across the full drug development lifecycle, from preclinical stages through commercial manufacturing.

The firm's technical platform combines advanced analytical instrumentation — including LC-HRMS, LC-MS/MS, GC-MS, NMR spectroscopy (1H, 13C, 31P, 19F), XRPD, DSC, TGA, ICP-MS/OES, SEM, Malvern Mastersizer, and Morphologi G3 — with manufacturing capabilities such as continuous flow processing and biocatalysis/catalyst design. Specialized service lines include nitrosamine and genotoxic impurity testing, high-potency/cytotoxic API release testing, reference standard qualification, physical characterization, and stability/forced degradation studies. Operations span facilities in the United States, Ireland, and South Korea.

AMPAC's business model is a fee-for-service CDMO contract structure with quote-based project pricing and multi-year contractual engagements. The go-to-market motion is direct enterprise sales targeting pharmaceutical companies, supported by industry events, technical content marketing, LinkedIn presence, and direct inquiry channels. The firm emphasizes collaborative partnerships and regulatory compliance as core value drivers, though no specific customer logos, revenue figures, or ownership structure details are publicly disclosed.

Name

AMPAC Fine Chemicals

Website

https://ampacfinechemicals.com

Company type

Private

Founded year

2005

Headcount range

501–1,000 employees

Short description

AMPAC Fine Chemicals is a US-based CDMO founded in 2005, headquartered in Rancho Cordova, California, specializing in fine chemicals, controlled substances, and highly potent APIs for pharmaceutical drugmakers across preclinical through commercial stages.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Chemical Manufacturing (325)

SIC

Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860), Services-Testing Laboratories (8734)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical contract manufacturing
• Custom API manufacturing
• Fine chemical synthesis
• Controlled substance manufacturing
• Highly potent API production

Headquarters

HQ city

Rancho Cordova

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Contract Analytical Testing Services: SK pharmteco operates as a CDMO providing fee-for-service analytical testing and development to pharmaceutical companies. Revenue is generated through contractual engagements for method development, validation, release testing, and stability studies across drug development phases.
2. API Manufacturing Services: Custom API contract manufacturing including clinical trial materials, validation batches, and commercial manufacturing services for small molecules.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

AMPAC Fine Chemicals is a US-based contract manufacturer of fine chemicals, controlled substances, and highly potent active pharmaceutical ingredients (APIs) for pharmaceutical companies. As part of the SK pharmteco CDMO network, it provides custom API manufacturing across clinical and commercial phases, alongside cGMP-compliant analytical testing services such as method development, validation, release testing, stability studies, and nitrosamine/genotoxic impurity testing.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom API Manufacturing Services
• Small Molecule Analytical & Testing Services
• Fine Chemicals Custom Manufacturing
• Controlled Substance API Manufacturing Specialized cGMP-compliant contract manufacturing of controlled substance APIs for pharmaceutical drugmakers, including handling of DEA-regulated substances and high-potency compounds.
• Highly Potent API Manufacturing Contract manufacturing of highly potent and cytotoxic APIs under strict cGMP compliance with specialized containment capabilities for pharmaceutical clients.
• Continuous Flow Processing Services Small molecule manufacturing services leveraging continuous flow processing capabilities for pharmaceutical clients, enabling improved safety, scalability, and process control for complex chemistries.
• Biocatalysis and Catalyst Design Services Specialized process development services in catalyst design and biocatalysis to support efficient and selective small molecule manufacturing for pharmaceutical clients.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Jayhawk Fine Chemicals LLCcoreStrategic or Co-development Partner · 9 December 2025Anupam Rasayan India Ltd acquired US-based Jayhawk Fine Chemicals LLC for $150 million to establish a US manufacturing presence. The deal includes an investment of about $40 million from the Indian company and $110 million from a global investment management firm. This acquisition provides onshore US manufacturing capabilities.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Cambrex: Pure-play small-molecule API CDMO offering custom development, analytical services, and commercial manufacturing — directly comparable to AMPAC's core offering and customer base.
• Hovione: Specialty small-molecule API CDMO with expertise in highly potent APIs, particle engineering, and continuous manufacturing — competes head-to-head with AMPAC in HPAPI and complex chemistry niches.
• Piramal Pharma Solutions: Global CDMO offering API development, HPAPI manufacturing, and integrated drug-substance/drug-product services — directly comparable in scope, scale, and customer profile to AMPAC.
• AGC Pharma Chemicals (AGC Biologics / AGC Chemicals): Specialty CDMO offering small-molecule API development and manufacturing, including HPAPIs — competes in similar customer segment with comparable custom synthesis capabilities.
• Johnson Matthey (Pharma Services): Pharma services division offering API development, HPAPI handling, and catalysis expertise — directly comparable in technologies (catalysis, flow chemistry) and customer base to AMPAC.
• Noramco: Leading controlled-substance and API CDMO serving pharma — directly comparable to AMPAC's controlled-substances and HPAPI niche, with similar DEA-regulated infrastructure.

Broad incumbents

• Lonza Small Molecules: World's largest CDMO with deep small-molecule API capabilities alongside biologics. Overlaps directly with AMPAC but is much broader in scale and integrated offering.
• Catalent: Major global CDMO with API and drug-product services that overlap AMPAC's offering, though Catalent is more diversified across biologics, softgel, and oral dose forms.
• WuXi STA (WuXi AppTec): Large Chinese-headquartered CDMO offering comprehensive small-molecule API and drug-product services — competes with AMPAC especially on cost-driven commercial API work, with increasing US/EU presence.
• Thermo Fisher Scientific (Patheon): Global CDMO offering API and drug-product services as part of its broader pharma services franchise — overlaps with AMPAC's integrated CDMO offering at much larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ampac

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMPAC Fine Chemicals